To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic retinopathy.

Inclusion Criteria:

• persistent new vessels,defined as fine retinal vessels with dilated buds or tips covered with hemorrhage or associated with recurrent vitreous hemorrhage or paucity of accompanying fibrous tissue and/or increased in extent compared to previous visit,unresponsive to complete panretinal laser photocoagulation performed at least 4 months prior;
• logarithm of minimum angle of resolution (logMAR) best-corrected visual acuity of 0.17 (Snellen equivalent, 20/30) or worse.

Exclusion Criteria:

• history of vitrectomy in the study eye;
• history of thromboembolic event (including myocardial infarction or cerebral vascular accident);
• major surgery within the prior 6 months or planned within the next 28 days;
• uncontrolled hypertension;
• known coagulation abnormalities or current use of anticoagulative medication other than aspirin.